Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell AbbVie Inc (ABBV) – AbbVie Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

AbbVie (ABBV) trades at $198.71, down 1.13% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth (2025: $61.2B) offset by declining net margins (6.9%) and elevated valuation ratios (P/E: 83.84). Recent positive clinical data for ELAHERE® and institutional buying activity provide support, while technical indicators show oversold conditions with RSI at 17.20 suggesting potential near-term bounce.
Outlook remains cautiously optimistic with 67.5% analyst buy ratings and $254.36 consensus target offering 28% upside. Key risks include patent cliffs, debt levels ($60.34B long-term), and margin pressure. The dividend aristocrat's 5.48% growth and pipeline developments position ABBV for recovery if execution continues.
Read full analysis

Key Stats

  • Market Cap
    $351.47B
  • Sector
    Health
  • 3M Drawdown
    -15.87%
  • Enterprise Value
    $413.71B
  • Dividend Yield
    3.48%
  • Typical Hold Time
    90 days
$199.04
52W Low: $177.44
14 May 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $351.47B, with an enterprise value of $413.71B. Over the past 52 weeks, AbbVie Inc has traded between a low of $177.44 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -15.87%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.48%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.


Technical Indicators
|
|
|
Overall Summary
Bearish (4)Neutral (10)Bullish (13)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $351.47B
  • Sector
    Health
  • 3M Drawdown
    -15.87%
  • Enterprise Value
    $413.71B
  • Dividend Yield
    3.48%
  • Typical Hold Time
    90 days
$199.04
52W Low: $177.44
14 May 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $351.47B, with an enterprise value of $413.71B. Over the past 52 weeks, AbbVie Inc has traded between a low of $177.44 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -15.87%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.48%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!